Premaitha pushing on in spite of Illumina prenatal testing patent lawsuit
This article was originally published in Clinica
UK noninvasive prenatal testing specialist Premaitha Health has been dealt a blow after larger rival Illumina sued it for patent infringement. But while Premaitha CEO Stephen Little described the development as a “nuisance,” he is confident that the firm’s technology does not infringe any third-party IP, he told Clinica.
You may also be interested in...
Noninvasive prenatal testing specialist Premaitha Health has agreed to acquire Taiwan's Yourgene Bioscience, enabling the UK company to expand its presence in Asia. The deal also offers an important market that has not been tainted by ongoing patent litigation between Premaitha and US next-generation sequencing firm Illumina.
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.